Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.66)
# 4,048
Out of 5,182 analysts
57
Total ratings
30.61%
Success rate
-30.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics | Initiates: Buy | $4 | $1.80 | +122.22% | 1 | Mar 4, 2026 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $1 | $4.47 | -77.63% | 1 | Jan 5, 2026 | |
| ARDX Ardelyx | Assumes: Buy | $11 | $5.94 | +85.19% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $18.82 | +64.72% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.32 | +1,339.39% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $14.69 | +42.95% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $5.45 | -8.26% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.52 | +952.63% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $0.24 | +50,747.46% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $32.11 | -22.14% | 2 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $70.50 | - | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,000 | $0.87 | +228,916.37% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.34 | +422.39% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $6.03 | +65.84% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $11.98 | +400.83% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $0.87 | +591.24% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.56 | +181.27% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.89 | +12,598.41% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $1.59 | +11,346.54% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $4,500 → $2,000 | $2.77 | +72,102.17% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.72 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.16 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.56 | +177.78% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $7.02 | +149,472.65% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $2.28 | +1,522.81% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $76.99 | +289.66% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $761.85 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $95.93 | -7.22% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $131.60 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.13 | +29,634.51% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.96 | +354.55% | 1 | Mar 19, 2020 |
Inhibikase Therapeutics
Mar 4, 2026
Initiates: Buy
Price Target: $4
Current: $1.80
Upside: +122.22%
Akari Therapeutics,
Jan 5, 2026
Initiates: Buy
Price Target: $1
Current: $4.47
Upside: -77.63%
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.94
Upside: +85.19%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $18.82
Upside: +64.72%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.32
Upside: +1,339.39%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $14.69
Upside: +42.95%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $5.45
Upside: -8.26%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.52
Upside: +952.63%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $0.24
Upside: +50,747.46%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $32.11
Upside: -22.14%
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $70.50
Upside: -
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $0.87
Upside: +228,916.37%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.34
Upside: +422.39%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $6.03
Upside: +65.84%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $11.98
Upside: +400.83%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $0.87
Upside: +591.24%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.56
Upside: +181.27%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.89
Upside: +12,598.41%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $1.59
Upside: +11,346.54%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $4,500 → $2,000
Current: $2.77
Upside: +72,102.17%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $10.72
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.16
Upside: -
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $7.56
Upside: +177.78%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $7.02
Upside: +149,472.65%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $2.28
Upside: +1,522.81%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $76.99
Upside: +289.66%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $761.85
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $95.93
Upside: -7.22%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $131.60
Upside: -
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.13
Upside: +29,634.51%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.96
Upside: +354.55%